McCormick falls as Unilever Foods deal raises dilution and leverage concerns

MKCMKC

McCormick shares are sliding after announcing a $44.8 billion combination with Unilever’s Foods business that leaves Unilever and its shareholders owning about 65% of the combined company. Investors are also weighing the $15.7 billion cash component and related financing needs, despite McCormick reporting strong Q1 sales growth and reaffirming its 2026 outlook.

1) What’s moving the stock today

McCormick (MKC) is trading lower today as the market digests a newly announced agreement to combine McCormick with Unilever’s Foods business in a transaction that implies an enterprise value of about $44.8 billion for Unilever Foods. The structure is drawing scrutiny because Unilever and its shareholders are expected to own roughly 65% of the combined company, leaving current McCormick shareholders with about 35%—a setup that can pressure the stock on perceived dilution and control concerns.

2) Deal terms investors are focused on

Beyond ownership, investors are focused on the cash-and-equity mix. McCormick is set to deliver $15.7 billion in cash plus stock value equivalent to about $29.1 billion, and the company lined up $15.7 billion of committed bridge financing while targeting longer-term financing ahead of closing. That funding need can raise questions about leverage, interest expense, and the combined company’s flexibility for buybacks or dividend growth in the near term.

3) Fundamentals and near-term debate

The selloff is happening even as McCormick posted strong first-quarter results (ended Feb. 28, 2026), including a sharp jump in net sales and a reaffirmed 2026 outlook. The near-term debate is whether the scale and brand portfolio from Unilever Foods can translate into durable growth and synergies fast enough to offset integration complexity and the balance-sheet burden implied by the cash portion and financing plan.

4) What to watch next

Key catalysts now shift to transaction details and execution: financing updates (debt terms, ratings impact), synergy and cost estimates, regulatory and shareholder approval timelines, and any changes to standalone guidance as deal costs ramp. Investors will also watch whether management clarifies capital allocation priorities and targets for deleveraging after the transaction closes.